The CRISPR field faced sharp contrasts this week: Intellia disclosed a death in its MAGNITUDE Phase III program and is awaiting FDA communication on the event, while CRISPR Therapeutics reported early clinical data showing a gene‑editing treatment halved cholesterol and triglycerides in an initial cohort. The juxtaposition underscores both the promise of in‑vivo editing and the safety scrutiny that can quickly stall late‑stage programs.